Abstract: The compounds represented by Formula (I), which are peripheral alkyl and alkenyl chains extended benzene derivatives, are useful as dual autotaxin (ATX)/histone deacetylase (HD AC) inhibitors. These compounds may be included in a pharmaceutical composition along with a pharmaceutically acceptable carrier, and be used in a therapeutically effective amount for prophylaxis or treatment of various diseases and disorders.

Abstract: The present disclosure provides a sustained release formulation of opioid receptor antagonists comprising a sustained release granule comprising at least one of the opioid receptor antagonist, at least one of pharmaceutical acceptable carrier, and a pH-dependent polymer, wherein the sustained release granule is coated with the pH-dependent polymer, and the opioid receptor antagonist is selected from the group consisting of Nalmefene, Naltrexone, or a salt thereof.

Abstract: The present invention provides a method of treating stroke or reducing nerve injury comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or formula (II) wherein W represents R1 represents R2 represents R3 represents R4 represents and R represent H or alkyl groups of C1-C6.

Abstract: The disclosure is related to a method for treating stroke or reducing nerve injury, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound isolated and purified from Antrodia camphorata fruiting body by methanol extraction. In particular, the compound is dehydroeburicoic acid, dehydrosulphurenic acid or 4,7-Dimethoxy-5-methyl-1,3-benzodioxole.

Abstract: A method for treating liver fibrosis. The method includes administering to a subject suffering from liver fibrosis a pharmaceutically active extract obtained from a Boehmeria species. Also disclosed is a method for regenerating liver tissue and a method for improving a liver function.

Abstract: The present invention relates to new medical uses of morphinans such as naltrexone, nalmefene and their related derivatives. The present invention relates to Toll-like receptor 4 (TLR4) antagonist compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of autoimmune liver diseases including but not limited to autoimmune hepatitis.

Abstract: An extract of Cynanchum sp. in use of arthritis treatment is provided. The extract of Cynanchum sp. and an active ingredient contained therein, antofine, are applicable to a method, pharmaceutical composition and dietary supplement for treatment of arthritis. A mass production of antofine from plant extracts is also provided.

Abstract: The present invention relates to new medical uses of morphinans such as naltrexone, nalmefene and their related derivatives. The present invention relates to Toll-like receptor 4 (TLR4) antagonist compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of autoimmune liver diseases including but not limited to autoimmune hepatitis.

Abstract: A method for treating or relieving inflammatory bowel disease (IBD) is provided, including administering an extract of Bupleurum as an active ingredient to a subject. The Bupleurum may be selected from the group consisting of Bupleurum krylovianum, Bupleurum chinense, Bupleurum commelynoideum, Bupleurum scorzonerifolium, Bupleurum triradiatum, Bupleurum falcatum, Bupleurum kaoi and a combination thereof.

Abstract: A pharmaceutical composition for alleviating or treating gout and the applications thereof are provided. The pharmaceutical composition includes p-coumaryl diacetate as an active ingredient.

Abstract: An extract of Cynanchum sp. in use of arthritis treatment is provided. The extract of Cynanchum sp. and an active ingredient contained therein, antofine, are applicable to a method, pharmaceutical composition and dietary supplement for treatment of arthritis. A mass production of antofine from plant extracts is also provided.

Abstract: A method for treating liver fibrosis. The method includes administering to a subject suffering from liver fibrosis a pharmaceutically active extract obtained from a Boehmeria species. Also disclosed is a method for regenerating liver tissue and a method for improving a liver function.

Abstract: A pharmaceutical composition with an immunomodulating function is provided, including an extract of Bupleurum obtained by grinding the Bupleurum, adding the ground Bupleurum to a solvent and isolating the extract from the solvent, wherein the Bupleurum comprises Bupleurum krlovianum, Bupleurum longiradiatum, Bupleurum smithii, Bupleurum pusillum, Bupleurum longicaule, Bupleurum salicifolium, Bupleurum scorzonerifolium and Bupleurums with at least one of the nucleotide sequences selected from a group consisting of SEQ ID NOs. 1˜6 and a nucleotide sequence with no more than 1% of the nucleotide sequence divergences of SEQ ID NOs. 1˜6, or combinations thereof.

Abstract: Disclosed herein is a hydrophilic foam. The hydrophilic foam includes a polyurethane matrix having a plurality of cells. The cells are capable of retaining water in an amount of least about 8 grams of water per gram of the hydrophilic foam.

Abstract: A pharmaceutical composition prepared from a Boehmeria species. This composition can be used to improve liver function and treat liver disease, and promoting liver tissue regeneration.

Abstract: A pharmaceutical composition with an immunomodulating function is provided, including an extract of Bupleurum obtained by grinding the Bupleurum, adding the ground Bupleurum to a solvent and isolating the extract from the solvent, wherein the Bupleurum comprises Bupleurum krlovianum, Bupleurum longiradiatum, Bupleurum smithii, Bupleurum pusillum, Bupleurum longicaule, Bupleurum salicifolium, Bupleurum scorzonerifolium and Bupleurums with at least one of the nucleotide sequences selected from a group consisting of SEQ ID NOs. 1˜6 and a nucleotide sequence with no more than 1% of the nucleotide sequence divergences of SEQ ID NOs. 1˜6, or combinations thereof.

Abstract: A pharmaceutical composition for treating or relieving inflammatory bowel disease (IBD) is provided. The pharmaceutical composition includes an extract of Bupleurum as an active ingredient, in which the Bupleurum is selected from the group consisting of Bupleurum krylovianum, Bupleurum chinense, Bupleurum commelynoideum, Bupleurum scorzonerifolium, Bupleurum triradiatum, Bupleurum falcatum, Bupleurum kaoi and a combination thereof.

Abstract: The invention is related to novel azulene-oxindole compounds having formula (I) shown below, wherein one of R1, R2 and R3 represents a moiety of formula (II), each of A1 and A2 independently is nitrogen, oxygen or sulfur, each of the others of R1, R2, R3, R1, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 is as recited in the specification. The novel compound potentially inhibits multiple kinases and thus can be used to treat some disease like cancer or inflammatory.

Abstract: Disclosed herein is a hydrophilic foam. The hydrophilic foam includes a polyurethane matrix having a plurality of cells. The cells are capable of retaining water in an amount of least about 8 grams of water per gram of the hydrophilic foam.

Abstract: A composition for reducing the activity of a cervical cancer cell is provided. The composition includes at least one of the following compounds: isopsoralen, triptolide, baicalein, gallic acid, quercetin, gossypol-acetic acid, baicalin, berberine hydrochloride, and derivatives thereof in a sufficient amount to reduce the activity of the cervical cancer cell in the subject.